Study identifier:D1532C00077
ClinicalTrials.gov identifier:NCT01931761
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Single-centre, Non-randomised, Open-label, Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-selumetinib in Healthy Male Volunteers
Solid tumours
Phase 1
Yes
[C14] selumetinib (oral)
Male
6
Interventional
50 Years - 65 Years
Allocation: N/A
Endpoint Classification: Bio-availability Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verified 01 Feb 2017 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: [C14] selumetinib 75mg single dose [C14] selumetinib 75mg single dose | Drug: [C14] selumetinib (oral) Single oral administration [C14] 75mg Other Name: Selumetinib |